Latest News by Industry

Technology

Show more

Moody's credit rating upgrade for Cyprus opens the door to investment, president says

•

Nov 23, 2024

Stock market today: Wall Street gains ground as it notches a winning week and another Dow record

•

Nov 22, 2024

Supreme Court allows multibillion-dollar class action to proceed against Meta

•

Nov 22, 2024

Oil & Gas

Show more

ExxonMobil could partner up with Eni and Total to jointly develop natural gas deposits off Cyprus

•

Nov 22, 2024

Stock market today: Wall Street rises following last week's slide

•

Nov 18, 2024

What to know about Chris Wright, Trump's choice to run the Energy Department

•

Nov 18, 2024

Healthcare

Show more

Justice Department sues to block UnitedHealth Group's $3.3 billion purchase of Amedisys

•

Nov 12, 2024

Stock market today: Wall Street drifts lower as the Trump trade cools

•

Nov 12, 2024

Natera: Q3 Earnings Snapshot

•

Nov 12, 2024

Manufacturing

Show more

Stock market today: Wall Street gains ground as it notches a winning week and another Dow record

•

Nov 22, 2024

Stock market today: Wall Street rises with Nvidia as bitcoin bursts above $99,000

•

Nov 21, 2024

Nvidia is Wall Street's most valuable company. How it got there, by the numbers

•

Nov 21, 2024

Taysha Gene Therapies, Inc. revenue decreases to $4.71 million in quarter ended Mar 31, 2023 from previous quarter

By USInMinutes - May 14, 2023, 11:57 AM ET

Last Updated - Jul 18, 2023, 03:28 PM EDT

Taysha Gene Therapies, Inc. revenue decreases to $4.71 million in quarter ended Mar 31, 2023 from previous quarter

Key fundamental financials
loss of $17.62 million
Revenue of $4.71 million

Current Reporting	Revenue	Net Income	Profit/Loss
Mar 2023	$4.71 million	$17.62 million	loss

Taysha Gene Therapies, Inc. [TSHA] has reported $17.62 million loss for the fiscal quarter ending Mar 31, 2023.

Revenue for the quarter was $4.71 million with operating income of $16.56 million.

The Dallas, Texas (TX)-based company operating in the biological products, except diagnostic substances sector has total shareholders equity of $14.95 million.

This is a developing story. Click here to receive updates.

------------

NewsInMinutes, an offering of 10kInfo, Inc., brings you news on the latest regulatory filings. Subscribe to additional news alerts here.